Cargando…
A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
Autores principales: | Uy, Geoffrey, Stewart, Stanford, Baughman, Jan, Rettig, Michael, Chichili, Gurunadh, Bonvini, Ezio, Wigginton, Jon, Lechleider, Robert, DiPersio, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288763/ http://dx.doi.org/10.1186/2051-1426-2-S3-P87 |
Ejemplares similares
-
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
por: Hurwitz, Herbert, et al.
Publicado: (2014) -
Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020) -
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
por: Baughman, Jan, et al.
Publicado: (2015) -
Mouse Genome Database (MGD) 2019
por: Bult, Carol J, et al.
Publicado: (2019) -
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)